Sodium Selenite Improves The Therapeutic Effect Of BMSCs Via Promoting The Proliferation And Differentiation, Thereby Promoting The Hematopoietic Factors
Overview
Authors
Affiliations
Purpose: Sodium selenite (NaSeO) has been known to restore the antioxidant capacity of bone marrow mesenchymal stem cells (BMSCs), reduce the production of reactive oxygen species (ROS) in the cells, and promote cell proliferation and inhibit cell apoptosis. However, it is still not clear whether selenium can mediate the differentiation and inhibit the induced hemagglutination of BMSCs. In this study, we attempted to explore the effect of NaSeO on these aspects of BMSCs.
Methods: We evaluated the fate of the MSCs isolated from the bone marrow of mice by studying their differentiation and proliferation after treatment with NaSeO. We also simultaneously evaluated the coagulation reaction induced by NaSeOtreated BMSCs in vitro.
Results: While the mice-derived BMSCs expressed CD44, CD73, CD90, and CD105, they did not express CD45. The morphology of the derived cells was homogeneously elongated. These results showed that the isolated cells are indeed BMSCs. We found that 0.1 μM and 1 μM of NaSeO promoted the proliferation and apoptosis of BMSCs, respectively. This showed that NaSeO can be toxic and exert certain side effects on the BMSCs. The results of the osteogenic and adipogenic assay showed that 0.1 μM NaSeO could significantly promote the osteogenic and adipogenic differentiation of BMSCs by upregulating the lipid factors (LPL and PPRAG) and osteogenic factors, RUNX2, COL1, and BGP, in a concentration-dependent manner. Coagulation experiments in animals (mice and rats) revealed that NaSeO can reduce the coagulation time of BMSCs in a concentration-dependent manner, which is related to the high expression of hematopoietic factors (SDF-1α, GM-CSF, IL-7, IL-8, IL-11, and SCF).
Conclusion: NaSeO promotes the proliferation and differentiation as well as reduces the coagulation time of BMSCs, and this effect might enhance the therapeutic effect of BMSCs.
Ji J, Wu S, Bao X, Liu S, Ye Y, Liu J Sci Rep. 2023; 13(1):19560.
PMID: 37949959 PMC: 10638393. DOI: 10.1038/s41598-023-46813-6.
Rahimi B, Panahi M, Lotfi H, Khalili M, Salehi A, Saraygord-Afshari N BMC Complement Med Ther. 2023; 23(1):131.
PMID: 37098557 PMC: 10127330. DOI: 10.1186/s12906-023-03952-7.
Yao Y, Jia W, Zeng X, Wang Y, Hu Q, Yu S Evid Based Complement Alternat Med. 2022; 2022:4388919.
PMID: 36034957 PMC: 9410791. DOI: 10.1155/2022/4388919.
Sun Y, Xu J, Lv S, Xu Z, Li L, Li Y Front Bioeng Biotechnol. 2022; 10:811128.
PMID: 35223785 PMC: 8867013. DOI: 10.3389/fbioe.2022.811128.
Xu J, Xu D, Yu Z, Fu Z, Lv Z, Meng L Biosci Rep. 2021; 42(1).
PMID: 34750610 PMC: 8703023. DOI: 10.1042/BSR20203363.